Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung.
D000284:Administration, Oral; D000588:Amines / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D005069:Evaluation Studies as Topic; D006801:Humans; D007273:Injections, Intramuscular; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced; D012075:Remission, Spontaneous; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014227:Triazines / Q000008:administration & dosage* / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
D000588:Amines; D000970:Antineoplastic Agents; D014227:Triazines; D008727:Methotrexate